ArticlePolymers2014
Addressing the Inflammatory Response to Clinically Relevant Polymers by Manipulating the Host Response Using ITIM Domain-Containing Receptors.
Article in Polymers, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- Polydioxanone implants: A systematic review on safety and performance in patients.Journal of biomaterials applications · 2020Pooled it
- Dynamic stiffness enables stage-specific properties mediating functional endothelialization on vascular implants.Science advances · 2026Article
- Innovative Strategies of Reprogramming Immune System Cells by Targeting CRISPR/Cas9-Based Genome-Editing Tools: A New Era of Cancer Management.International journal of nanomedicine · 2023Review
- Bio-inspired hemocompatible surface modifications for biomedical applications.Progress in materials science · 2022Article
- The Application of CRISPR/Cas9 Technology for Cancer Immunotherapy: Current Status and Problems.Frontiers in oncology · 2021Review
- Mitigation of Blood Borne Cell Attachment to Metal Implants through CD47-Derived Peptide Immobilization.Journal of visualized experiments : JoVE · 2020Article
- Stability and bioactivity of pepCD47 attachment on stainless steel surfaces.Acta biomaterialia · 2020Article
- Evaluation of Local Tissue Reaction After the Application of a 3D Printed Novel Holdfast Device for Left Atrial Appendage Exclusion.Annals of biomedical engineering · 2020Article
- CRISPRed Macrophages for Cell-Based Cancer Immunotherapy.Bioconjugate chemistry · 2018Article
- The Role of the Chemokine System in Tissue Response to Prosthetic By-products Leading to Periprosthetic Osteolysis and Aseptic Loosening.Frontiers in immunology · 2017Review
- The use of CD47-modified biomaterials to mitigate the immune response.Experimental biology and medicine (Maywood, N.J.) · 2016Review
- Enhanced biocompatibility of CD47-functionalized vascular stents.Biomaterials · 2016Article
- The Quest for Anti-inflammatory and Anti-infective Biomaterials in Clinical Translation.Frontiers in bioengineering and biotechnology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Tissue contacting surfaces of medical devices initiate a host inflammatory response, characterized by adsorption of blood proteins and inflammatory cells triggering the release of cytokines, reactive oxygen species (ROS) and reactive nitrogen species (RNS), in an attempt to clear or isolate the foreign object from the body. This normal host response contributes to device-associated pathophysiology and addressing device biocompatibility remains an unmet need. Although widespread attempts have been made to render the device surfaces unreactive, the establishment of a completely bioinert coating has been untenable and demonstrates the need to develop strategies based upon the molecular mechanisms that define the interaction between host cells and synthetic surfaces. In this review, we discuss a family of transmembrane receptors, known as immunoreceptor tyrosine-based inhibitory motif (ITIM)-containing receptors, which show promise as potential targets to address aberrant biocompatibility. These receptors repress the immune response and ensure that the intensity of an immune response is appropriate for the stimuli. Particular emphasis will be placed on the known ITIM-containing receptor, Signal Regulatory Protein Alpha (SIRPhα), and its cognate ligand CD47. In addition, this review will discuss the potential of other ITIM-containing proteins as targets for addressing the aberrant biocompatibility of polymeric biomaterials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.